Akero Therapeutics Inc. (NASDAQ: AKRO) stock closed at 46.04 per share at the end of the most recent trading day (a -2.99% change compared to the prior day closing price) with a volume of 900.91K shares and market capitalization of 2.56B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 17 people. Akero Therapeutics Inc. CEO is Andrew Cheng.

The one-year performance of Akero Therapeutics Inc. stock is 23.4%, while year-to-date (YTD) performance is -15.99%. AKRO stock has a five-year performance of %. Its 52-week range is between 32.21 and 58.38, which gives AKRO stock a 52-week price range ratio of 52.85%

Akero Therapeutics Inc. currently has a PE ratio of -13.30, a price-to-book (PB) ratio of 6.10, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -42.69%, a ROC of -43.78% and a ROE of -47.44%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Akero Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.69 for the next earnings report. Akero Therapeutics Inc.’s next earnings report date is 03rd Nov 2023.

The consensus rating of Wall Street analysts for Akero Therapeutics Inc. is Strong Buy (1), with a target price of $52.4, which is +13.81% compared to the current price. The earnings rating for Akero Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Akero Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Akero Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 18.99, ATR14 : 2.30, CCI20 : -87.66, Chaikin Money Flow : 0.01, MACD : -0.22, Money Flow Index : 51.34, ROC : -9.15, RSI : 47.96, STOCH (14,3) : 28.46, STOCH RSI : 0.53, UO : 50.78, Williams %R : -71.54), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Akero Therapeutics Inc. in the last 12-months were: Andrew Cheng (Option Excercise at a value of $57 503), Andrew Cheng (Sold 85 000 shares of value $3 917 423 ), Catriona Yale (Sold 20 000 shares of value $855 843 ), Cheng Andrew (Sold 0 shares of value $-331 966 ), Cheng Andrew (Option Exercise at a value of $183 600), Cheng Andrew (Sold 203 226 shares of value $9 256 239 ), Heyman Tomas (Option Excercise at a value of $651 040), Jane P. Henderson (Sold 0 shares of value $-280 400 ), Jane P. Henderson (Sold 17 502 shares of value $941 433 ), Jonathan Young (Option Excercise at a value of $160 250), Jonathan Young (Sold 33 777 shares of value $1 658 113 ), Rolph Timothy (Sold 0 shares of value $-24 400 ), Rolph Timothy (Sold 78 709 shares of value $4 312 393 ), Seth L. Harrison (Sold 352 721 shares of value $15 056 764 ), Timothy Rolph (Option Excercise at a value of $314 016), Timothy Rolph (Sold 45 000 shares of value $1 899 613 ), White William Richard (Sold 606 shares of value $33 427 ), William R. White (Option Excercise at a value of $280 360), William R. White (Sold 40 000 shares of value $1 791 723 ), Yale Catriona (Sold 0 shares of value $-36 538 ), Yale Catriona (Sold 55 685 shares of value $2 856 183 ), Young Jonathan (Sold 0 shares of value $-5 442 ), Young Jonathan (Sold 9 315 shares of value $509 251 )